JPRN-UMIN000029905已完成未知
Effect of canagliflozin in type 2 diabetic patients with microalbuminuria in Japanese population - CANPIONE study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Use of SGLT2 inhibitor <= 12 weeks prior to informed consent 2. Known allergies or hypersensitivity to canagliflozin or other SGLT2 inhibitors 3. History of severe diabetic ketosis (including ketoacidosis), diabetic coma or pre-coma 4. Severe infection, pre- or post-surgery (ie, requiring general anesthesia) or severe trauma at time of informed consent or visit 3 5. Urinary tract infection or genital infection at time of informed consent or visit 3 6. Underlying renal disease other than diabetic nephropathy at time of informed consent or visit 3 7. New York Heart Association Class IV cardiac disease at time of informed consent or visit 3 8. Severe hypertension (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 110 mmHg) at time of informed consent or visit 3 9. History of arteriosclerosis obliterans and/or foot ulcer and/or limb amputation 10. Pregnant, possibly pregnant, breast-feeding or planning to become pregnant during the study 11. Medical history of cancer and/or treatment for cancer within the last 5 years at time of informed consent or visit 3 12. Severe liver disease at time of informed consent or visit 3 13. Treatment with systemic steroids at time of informed consent or visit 3 14. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) at time of informed consent or visit 3 15. Reduction in eGFR >= 30% from visit 1 to visit 3 16. Any condition that, in the opinion of the investigator, would compromise the subject's well-being or ability to perform the study requirements
研究者
相似试验
进行中（未招募）
不适用
Effect of canagliflozin in type 2 diabetic patients with microalbuminuria in Japanese populatioType 2 diabetes with microalbuminuriaJPRN-jRCTs061180047Miyamoto Satoshi110
已完成
不适用
The study of effects of Canagliflozin ON T2DM patients' glycemic value Reduction and On Lowering dosage of insulin therapyType 2 diabetesJPRN-UMIN000018085niversity of Occupational and Environmental Health58
招募中
不适用
Effect of Canagliflozin in Non-diabetic overweight and obesity Patients with albuminuria: A Randomized, Double-blind, Placebo-controlled TrialEffect of Canagliflozin in Non-diabetic overweight and obesity Patients.Canagliflozin and Non-diabetic overweight and obesity PatientsTCTR20190203003Rachadaphiseksompot Endorsement Fund80
尚未招募
不适用
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liverJPRN-UMIN000026549Kagawa prefectural central hospital25
已完成
不适用
Effects of canagliflozin on the glycemic control and plasma GLP-1 levels.Type 2 diabetes mellitusJPRN-UMIN000018345akakinen clinic45